New Hope for Men with Prostate Cancer in Biochemical Relapse
Biochemical relapse is a challenging time for men with prostate cancer. We know it’s a time when the cancer is becoming active again, because the PSA blood test begins to rise after a patient has had prostate directed treatment (such as surgery, radiation, focal therapy or some combination), but it... More
A Personalized Approach: The Role of Commercially Available Genetic Tests
Prostate Cancer is the most commonly diagnosed malignancy in American men. Patients and their doctors face many challenges when it comes to prostate cancer, particularly the broad spectrum of how it behaves (slow growing versus aggressive) and the multitude of treatment options available for localized and metastatic disease (when cancer... More
Treatment Options: When Cancer Returns After Radiation
After prostate cancer is treated, patients usually undergo a blood test called PSA. PSA stands for Prostate Specific Antigen and is a simple blood test that gives a number. After treatment, that number should be low. If it starts to increase, that can be a signal of cancer coming back, More
Sometimes MORE is better
When given the option of another piece of cake, most toddlers will automatically respond with more cake, because more is better, right? In medicine sometimes more is better, and sometimes it’s not. Recently published in the New England Journal of Medicine (July 27, 2017)1,2 were two large clinical trials looking at... More
BU Today: Trustee Gives $10 Million to Redirect Fight against Prostate Cancer
Shipley Foundation gift will fund research in personalized medicine Each year, more than 100,000 men diagnosed with prostate cancer in the United States undergo a prostatectomy, a surgical procedure that leaves most of them unable to function sexually and many of them incontinent. The majority would live just as long with... More
Daily Free Press: BU trustee Richard Shipley establishes cancer research center, explores “humane” treatment
Boston University trustee Richard Shipley, a School of Management Class of 1972 graduate, donated $10.5 million to the BU School of Medicine for the creation of the Shipley Prostate Cancer Research Center on the BU Medical Campus, BU spokesperson Colin Riley said. Riley confirmed that Shipley’s donation will go toward finding... More
Philanthropy News Digest: BU Receives $10.5 Million for Prostate Cancer Research Institute
Boston University has announced a $10.5 million grant from trustee and alumnus Richard C. Shipley to create a prostate cancer research center at its School of Medicine. Full Story at: Philanthropynewsdigest.org